Pablo B.
- Country
- France
- Department
- N/A
Research Overview
- Phase 3 Evaluation of Exagamglogene Autotemcel Efficacy and Safety in Severe Sickle Cell Disease (βS/βC Genotype) with Plerixafor and Busulfan
- Evaluation of Etavopivat, a Pyruvate Kinase Activator, in a Randomized, Placebo-Controlled Study for Sickle Cell Disease in Patients Aged 12 to 65 Years
- Efficacy and Safety of Crizanlizumab in Adolescent and Adult Patients with Sickle Cell Disease Experiencing Vaso-Occlusive Crises: A Phase III Randomized Study
Data & Insights
Has run more than one trial at 40 of 72 partner sites.
Specializations
Hemoglobinopathies Research
This investigator specializes in treating sickle cell disease and its various manifestations, with particular focus on developing therapeutic approaches for managing vaso-occlusive episodes.
- Sickle Cell Disease Management
- Vaso-occlusive Crisis Prevention
- Hemoglobin Optimization
Their work encompasses novel therapeutic approaches for improving disease outcomes in adolescent and adult populations.
Thalassemia Studies
The investigator conducts research in both transfusion-dependent and non-transfusion-dependent thalassemia, focusing on alpha and beta variants of the condition.
- Alpha-Thalassemia Treatment
- Beta-Thalassemia Management
- Transfusion Burden Reduction
Their research addresses therapeutic interventions for various thalassemia manifestations and complications.
Hematologic Innovations
The investigator explores innovative treatments for blood disorders, with emphasis on developing new therapeutic approaches for inherited hemoglobin disorders.
- Novel Therapeutic Agents
- Anemia Management
- Disease-Modifying Treatments
Their work includes evaluation of emerging therapies for severe hematologic conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.